|
Dr. Smiley joined Inspire in August 2005. Her responsibilities include serving as Medical Safety Officer for the Company and assisting the executive management team in developing and overseeing medical strategies related to product development. She develops and guides regulatory strategy and serves as a medical and scientific consultant to the Company's research and marketing teams. During her career, Dr. Smiley has been involved with the development of more than 20 pharmaceutical compounds, including 14 approved products, such as first-in-class drugs, Fuzeon® (enfuvirtide) HIV treatment, Retrovir® (zidovudine) HIV treatment, also known as AZT, and Zovirax® (acyclovir) anti-viral treatment. Prior to joining Inspire, Dr. Smiley served as Senior Vice President of Regulatory Affairs, Compliance, and Drug Safety for Trimeris, Inc. She joined Trimeris as Chief Medical Officer and Senior Vice President of Clinical Research in January 2001. Dr. Smiley spent 13 years at GlaxoWellcome, Inc. (and its predecessors) serving most recently as Vice President of HIV and Opportunistic Infections Clinical Development and Director of the Infectious Diseases Department. Dr. Smiley has held teaching positions at the University of North Carolina at Chapel Hill School of Medicine since 1984, serving as Clinical Professor of Medicine since 1994. She holds an M.D. from the Duke University School of Medicine and a B.A. in Microbiology from the University of Kansas. | 